Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study

Objectives There are no real-world data describing infection morbidity in relapsed/refractory myeloma (RRMM) patients treated with anti-CD38 isatuximab in combination with pomalidomide and dexamethasone (IsaPomDex). In this UK-wide retrospective study, we set out to evaluate infections experienced b...

Descripción completa

Detalles Bibliográficos

Autores principales:	Faouzi Djebbari, Alexandros Rampotas, Grant Vallance, Fotios Panitsas, Nanda Basker, Gina Sangha, Beena Salhan, Farheen Karim, Al-Kaisi Firas, Amy Gudger, Loretta Ngu, Matt Poynton, Ho Pui Jeff Lam, Lowri Morgan, Laura Yang, Jennifer Young, Mairi Walker, Ismini Tsagkaraki, Laura Anderson, Saleena Rani Chauhan, Rebecca Maddams, Richard Soutar, Margarita Triantafillou, Steve Prideaux, Abubaker Obeidalla, Toby A. Eyre, Ceri Bygrave, Supratik Basu, Karthik Ramasamy
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Taylor & Francis Group 2022-12-01
Colección:	Hematology
Materias:	Infections isatuximab pomalidomide real-world myeloma
Acceso en línea:	https://www.tandfonline.com/doi/10.1080/16078454.2022.2082725
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!